

JAN. 14. 2004 4:16PM

NEEDLE & ROSENBERG

NO. 326

P. 1/7

RECEIVED
CENTRAL FAX CENTER

JAN 14 2004

NEEDLE & ROSENBERG

OFFICIAL

IMPORTANT FAX DOCUMENT

NEEDLE & ROSENBERG PC
SUITE 1000
999 PEACHTREE STREET
ATLANTA, GEORGIA 30309-3915
678-420-9300
NEEDLERROSENBERG.COM

DATE January 14, 2004
NAME Examiner G.R. Ewoldt
Group Art Unit 1642
COMPANY Commissioner for Patents
FAX NUMBER 703-305-3014

FROM Tina W. McKeon, Ph.D.
REFERENCE NO. 14028.0284U2
OUR FAX NUMBER 678-420-9301
NUMBER OF PAGES 7 (including cover)

CONFIDENTIALITY NOTE

The information which follows and is transmitted herewith is attorney privileged, trade secret and confidential information intended only for viewing and use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any review, use, communication, dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the above address.

OFFICIAL**ATTORNEY DOCKET NO. 14028.0284U2****Application No. 09/810,999****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**RECEIVED
CENTRAL FAX CENTER

JAN 14 2004

In re Application of)

Neville et al.)

Application No. 09/810,999)

Confirmation No. 6212)

Filed: March 16, 2001)

For: "USE OF IMMUNOTOXINS TO INDUCE)
TOLERANCE TO PANCREATIC ISLET)
TRANSPLANTATION")

Examiner: Ewoldt, Gerald R.

Art Unit: 1642

**AMENDMENT AND RESPONSE TO OFFICE ACTION
UNDER 37 C.F.R. § 1.111**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450NEEDLE & ROSENBERG, P.C.
Customer No. 23859

Sir:

This Amendment and Response to Office Action filed under 37 C.F.R. § 1.111 is responsive to the Office Action dated January 2, 2004, issued regarding the above-referenced patent application. This response is being re-submitted pursuant to the Office Action dated January 2, 2004. The response is the same as the previous response, except the text of claim 3 has been included.